Beta

Spending
Congress
Stocks
Lobbying

Spending
Congress
Stocks
Lobbying

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Congress
Stocks
Lobbying

ANNEXON BIOSCIENCES — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

ANNEXON BIOSCIENCES

via ENGEL BURNS

2nd Quarter (Apr 1 - June 30) · 2025Posted Jul 16, 2025Filing document ↗LDA record ↗

Income$10Kfee reported

Client

Name: ANNEXON BIOSCIENCES
Description: Pharmaceutical manufacturer
Location: California · United States of America

Registrant

Firm: ENGEL BURNS
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Health Issues
Rare disease policy, drug approval process
LobbyistsENGEL BURNS
TargetedHOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.